ZLAB

Business Context and Reporting Period

Company: Zai Lab Limited (Zai Lab)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Zai Lab is a commercial-stage, global biopharmaceutical company focused on oncology, immunology, neuroscience, and infectious disease. The company operates primarily in Greater China and the United States, commercializing seven approved products (ZEJULA, VYVGART/VYVGART Hytrulo, NUZYRA, OPTUNE, QINLOCK, XACDURO, and AUGTYRO) and advancing a robust pipeline of in-licensed and internally developed candidates.

Key Financial Metrics

Liquidity: As of December 31, 2025, the company held $789.6 million in cash, cash equivalents, and short-term investments. Management believes this is sufficient to fund operations for at least the next 12 months. The company has access to debt facilities totaling approximately $317.4 million, with $204.5 million drawn as of year-end.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 15% to $460.2 million, driven primarily by strong sales of XACDURO (+593% to $22.9 million) and NUZYRA (+41% to $60.8 million). ZEJULA remained the top revenue generator at $189.0 million (+1%).
• Expense Reduction: Net loss improved by 32% to $175.5 million. This was achieved through a 6% decrease in R&D expenses (to $220.9 million) and a 7% decrease in SG&A expenses (to $277.6 million), attributed to resource prioritization and efficiency efforts.
• Foreign Currency Impact: The company recorded a foreign currency gain of $19.6 million in 2025, compared to a loss of $15.1 million in 2024, primarily due to the appreciation of the RMB against the U.S. dollar.
• Inventory Provision: Cost of product revenue increased 30% to $190.5 million, partly due to a $12.3 million inventory write-down related to VYVGART Hytrulo in the fourth quarter.

Guidance, Outlook, and Risks

Outlook: Management expects revenues to continue increasing in 2026, driven by existing commercial products and recently approved indications (e.g., AUGTYRO for NTRK+ solid tumors, KarXT for schizophrenia). The company aims to advance its path to profitability by balancing commercial success with continued R&D investment.

Key Risks and Contingencies:

• Regulatory and Geopolitical: Significant risks associated with operating in mainland China, including data privacy laws, anti-corruption enforcement, and potential changes in U.S.-China trade relations.
• Profitability: The company has incurred losses since inception and anticipates continuing to incur losses for at least the next few quarters. Profitability depends on the commercial success of current and future products.
• Third-Party Dependence: Reliance on licensors (e.g., GSK, argenx, BMS) and CMOs for the supply of key products. Supply constraints impacted XACDURO sales in 2025.
• Intellectual Property: Risks related to patent expiration (e.g., OPTUNE patents projected to expire in 2026) and potential challenges to patent validity.

Investor Verification Checklist

• Product Launch Execution: Verify the commercial uptake and supply chain stability for newly launched products (XACDURO, AUGTYRO) and new indications (KarXT, AUGTYRO NTRK+).
• NRDL Pricing Impact: Monitor the impact of National Reimbursement Drug List (NRDL) price negotiations on margins, particularly for VYVGART and other core products.
• Cash Burn Rate: Track the trajectory of operating cash burn against the $789.6 million cash balance to assess runway to profitability.
• Debt Obligations: Review the terms of the $204.5 million short-term debt, including interest rate fluctuations and repayment schedules.
• Regulatory Approvals: Monitor the status of BLA/NDA submissions for pipeline assets like TIVDAK (cervical cancer) and Zoci (SCLC).